Tags

Type your tag names separated by a space and hit enter

Respiratory function during infancy in survivors of the INNOVO trial.
Pediatr Pulmonol. 2009 Feb; 44(2):155-61.PP

Abstract

RATIONALE

Despite encouraging reports suggesting that inhaled nitric oxide (iNO) appear to improve outcome in hypoxemic term and near term infants by improving oxygenation and reducing need for ECMO, the long-term benefits of iNO remain unclear. This study aimed to compare lung function at approximately 1 year in infants who were and were not randomly allocated to iNO as part of their neonatal management for severe respiratory failure at birth. Furthermore, results were compared to lung function of healthy infants.

METHODS

Maximal expiratory flow at functional residual capacity (V'maxFRC) was measured at approximately 1 year of age (corrected for any prematurity) in survivors of the INNOVO trial. Results were expressed as Z-scores, adjusted for sex and body size, based on data from healthy controls using identical techniques.

RESULTS

Technically satisfactory results were obtained in 30 infants (53% < 34 weeks gestation), 19 of whom were randomized to receive iNO V'maxFRC. Z-score was significantly reduced in infants with prior respiratory failure, whether or not they had been allocated to iNO (mean (SD) Z-score: -2.0 (1.2) and -2.6 (1.1), respectively, 95% CI difference; iNO vs. no iNO: -0.3; 1.6, P = 0.2). There was significant respiratory morbidity in both groups during the first year of life.

CONCLUSIONS

These results suggest that airway function remains reduced at 1 year of age following severe respiratory failure at birth, whether or not iNO is administered.

Links

Aggregator Full Text

Authors+Show Affiliations

Hoo AF
Portex Anaesthesia, Intensive Therapy and Respiratory Medicine Unit, UCL Institute of Child Health, London, UK. a.hoo@ich.ucl.ac.uk
Beardsmore CS
No affiliation info available
Castle RA
No affiliation info available
Ranganathan SC
No affiliation info available
Tomlin K
No affiliation info available
Field D
No affiliation info available
Elbourne D
No affiliation info available
Stocks J
No affiliation info available
INNOVO Trial Collaborating Group
No affiliation info available

MeSH

FemaleHumansInfantInfant, NewbornMaleNitric OxidePeak Expiratory Flow RateRandomized Controlled Trials as TopicRespiratory InsufficiencySeverity of Illness Index

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19148936

Citation

Hoo, Ah-Fong, et al. "Respiratory Function During Infancy in Survivors of the INNOVO Trial." Pediatric Pulmonology, vol. 44, no. 2, 2009, pp. 155-61.
Hoo AF, Beardsmore CS, Castle RA, et al. Respiratory function during infancy in survivors of the INNOVO trial. Pediatr Pulmonol. 2009;44(2):155-61.
Hoo, A. F., Beardsmore, C. S., Castle, R. A., Ranganathan, S. C., Tomlin, K., Field, D., Elbourne, D., & Stocks, J. (2009). Respiratory function during infancy in survivors of the INNOVO trial. Pediatric Pulmonology, 44(2), 155-61. https://doi.org/10.1002/ppul.20967
Hoo AF, et al. Respiratory Function During Infancy in Survivors of the INNOVO Trial. Pediatr Pulmonol. 2009;44(2):155-61. PubMed PMID: 19148936.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Respiratory function during infancy in survivors of the INNOVO trial. AU - Hoo,Ah-Fong, AU - Beardsmore,Caroline S, AU - Castle,Rosemary A, AU - Ranganathan,Sarath C, AU - Tomlin,Keith, AU - Field,David, AU - Elbourne,Diana, AU - Stocks,Janet, AU - ,, PY - 2009/1/17/entrez PY - 2009/1/17/pubmed PY - 2009/6/24/medline SP - 155 EP - 61 JF - Pediatric pulmonology JO - Pediatr Pulmonol VL - 44 IS - 2 N2 - RATIONALE: Despite encouraging reports suggesting that inhaled nitric oxide (iNO) appear to improve outcome in hypoxemic term and near term infants by improving oxygenation and reducing need for ECMO, the long-term benefits of iNO remain unclear. This study aimed to compare lung function at approximately 1 year in infants who were and were not randomly allocated to iNO as part of their neonatal management for severe respiratory failure at birth. Furthermore, results were compared to lung function of healthy infants. METHODS: Maximal expiratory flow at functional residual capacity (V'maxFRC) was measured at approximately 1 year of age (corrected for any prematurity) in survivors of the INNOVO trial. Results were expressed as Z-scores, adjusted for sex and body size, based on data from healthy controls using identical techniques. RESULTS: Technically satisfactory results were obtained in 30 infants (53% < 34 weeks gestation), 19 of whom were randomized to receive iNO V'maxFRC. Z-score was significantly reduced in infants with prior respiratory failure, whether or not they had been allocated to iNO (mean (SD) Z-score: -2.0 (1.2) and -2.6 (1.1), respectively, 95% CI difference; iNO vs. no iNO: -0.3; 1.6, P = 0.2). There was significant respiratory morbidity in both groups during the first year of life. CONCLUSIONS: These results suggest that airway function remains reduced at 1 year of age following severe respiratory failure at birth, whether or not iNO is administered. SN - 1099-0496 UR - https://www.unboundmedicine.com/medline/citation/19148936/Respiratory_function_during_infancy_in_survivors_of_the_INNOVO_trial_ L2 - https://doi.org/10.1002/ppul.20967 DB - PRIME DP - Unbound Medicine ER -